Results 201 to 210 of about 31,245 (265)

Equitable access to costly new drugs.

BMJ
Woods B, Ten Ham R, Claxton K.
europepmc   +1 more source

Emulsion Quality and Functional Properties of Natural Emulsion Systems with Xanthan Gum as a Stabilizer and Carrier of Compounds Based on Enzymatically Modified Mutton Tallow and Hemp Oil. [PDF]

Molecules
Kowalska M, Wozniak M, Zbikowska A, Szakiel J, Turek P.   +4 more
europepmc   +1 more source

Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025-2027. [PDF]

Health Econ Rev
Marcellusi A, Cazzato D, Guarnotta G, Aiello A, Bonfanti M, Bitonti R, Guardigni M, Lucchetti C, Luccini F, Canonico PL, Jommi C.   +10 more
europepmc   +1 more source

Medicaid Expansion and Retail Pharmacy Availability.

JAMA Health Forum
Kakani P, Lu J, Qato DM, Nicholson S, Schpero WL.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Economic Evaluation of Pharmaceuticals

PharmacoEconomics, 1992
The increased pressures on health care budgets have emphasised the need to demonstrate the value for money from health technologies. Most major pharmaceutical companies have therefore commissioned cost-benefit or cost-effectiveness analysis of their products. There is an assumed analogy between clinical trains, which are required for product licensing,
openaire   +4 more sources

Economic Evaluation of Pharmaceuticals

PharmacoEconomics, 1993
In recent years there has been a large increase in the number of economic evaluations of pharmaceuticals. Many of these studies have been commissioned by individual pharmaceutical companies, in support of new or existing products. In 2 countries, Australia and Canada (in the province of Ontario), draft guidelines issued by the government have ...
Michael Drummond, Frans Rutten, Antonio Brenna, Carlos Gouveia Pinto, Bruno Horisberger, Bengt Jönsson, Claude Le Pen, Joan Rovira, Matthias Graf von der Schulenburg, Harri Sintonen, Koen Torfs   +10 more
openaire   +2 more sources

The Economics of Pharmaceutical Policy in Ghana

International Journal of Health Services, 1980
Pharmaceutical expenditure in Ghana accounts for about one-third of the total recurrent costs of the Ministry of Health, but in isolation this figure is a misleading indicator of economic importance. In the primary care sector up to 75–80 percent of the running cost of a health center may be accounted for by pharmaceuticals, and because the Ghanaian ...
A, Barnett, A L, Creese, E C, Ayivor
openaire   +2 more sources